Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there is significant uncertainty regarding the level and timing of sales of Arestvyr™ and when and whether it will be approved by the U.S. FDA and corresponding health agencies around the world. We cannot predict with certainty if or when SIGA will begin recognizing profit on the sale thereof and there can be no assurance that any profits received by SIGA and paid to us will be significant. Furthermore, SIGA has filed an appeal with the Delaware Supreme Court challenging aspects of the Court of Chancery decision, and there can be no assurances that the decision will not be reversed or that the remedy will not otherwise be modified. In addition, we cannot predict how long the appeal will delay the receipt of payments, if any, from SIGA. Further, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for all of our product candidates, and with FDA's August 2012 clinical hold of SparVax®, it is unclear when, if ever, we can re-initiate human clinical trials for that product candidate. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

-- Tables Follow -- PHARMATHENE, INC.CONSOLIDATED BALANCE SHEETSDecember 31,20122011ASSETSCurrent assets:Cash and cash equivalents

$
2,701,517$   11,236,771Accounts receivable (billed)

2,432,6414,424,442Unbilled accounts receivable

4,114,4423,021,208Prepaid expenses and other current assets

547,245830,585Restricted cash

-100,000Total current assets'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... and Queens, New York (PRWEB) October 02, 2014 ... is pleased to announce funding received to investigate ... in Alzheimer’s disease. A grant award from the ... on Aging (NIA), National Institutes of Health (NIH) ... Novel AD Therapeutics." The company also received a ...
(Date:10/2/2014)... California (PRWEB) October 02, 2014 ... Livermore National Laboratory (LLNL) a grant today to ... researchers to better understand how the brain works ... project is part of NIH's efforts to support ... Neurotechnologies) Initiative, a new research effort to revolutionize ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , Oct. 2, ... a leader in synthetic biology, and Amneal ... manufacturer by volume in the U.S., today announced ... (ECC) for a target active pharmaceutical ingredient (API).  ... of the collaboration is to develop a consistent, ...
(Date:10/1/2014)... 1, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... and sale of high pressure-based sample preparation systems to ... been invited to present at the 2 nd ... , Poland.  The Conference will take place at the ... Richard T. Schumacher , President and CEO of PBI, ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4
... Genetics ,™ Inc., an innovative molecular diagnostics company developing the ... it completed the initial closing of a $14 million Series ... OrbiMed Advisors , Safeguard Scientifics, Inc. (NYSE: ... Proceeds from this financing will be used to augment commercial ...
... Want a see-through cellphone you can wrap around your wrist? ... Rice University chemist James Tour, whose lab has developed transparent, ... Tour revealed today in a talk at the national ... Diego that the new type of memory could combine with ...
... Centrix, a Nevada-based biotech corporation, announced this week its development ... a term used in programming wearable TheraEX (TM) skin ... field that surrounds all life forms. When ... in its basic form, it embodies seven major layers powered ...
Cached Biology Technology:Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 2Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 3Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 4Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 5AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches 2
(Date:9/30/2014)... almost any aquatic environment on Earth, but when the ... pushed to the limit. The amount of time needed ... how different species cope in the future, reveals a ... published in the scientific journal Proceedings of the ... thanks to increasing levels of greenhouse gases in the ...
(Date:9/30/2014)... to know what goes wrong with your muscles because of ... what "normal" actually is. That,s where a new research report ... FASEB Journal comes in. In the report, a ... molecules that can help scientists "see" which genes are active ... found never-before-detected gene activity and that men have approximately 400 ...
(Date:9/30/2014)... (September 30, 2014) People who suffer from asthma ... to control their asthma besides properly taking medications and ... article in the Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), asthma sufferers can ... lifestyle. The woman described in the Annals article improved ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... requirements of new names for algae, fungi and plants ... Melbourne in July 2011 initiated several important challenges to scientists, ... the Congress decisions, the open access journal PhytoKeys ... one each day for the first week of 2012, starting ...
... This release is available in German . ... this more often when kin or mates are present than ... evidence that they take the other group members, knowledge state ... Anthropology in Leipzig, Germany, and the University of St. Andrews, ...
... found that elderly people with higher levels of several vitamins ... performance on mental acuity tests and less of the brain ... produced just the opposite result. The study was among ... range of blood nutrient levels instead of basing findings on ...
Cached Biology News:Brave new world 2Brave new world 3I know something you don't know -- and I will tell you! 2Diet, nutrient levels linked to cognitive ability, brain shrinkage 2
Troponin I (22B11)...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... regulator and pressurized syringe holder for any researcher ... flow rate Microinjecting Fine microliter delivery ... added to any new or existing perfusion rig ... homemade. Connect to house air or a compressor ...
Biology Products: